Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of LY2775240 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY2775240
Drug: Placebo
Drug: Apremilast

First Posted Date: 2016-11-15

Last Posted Date: 2017-11-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 35

Registration Number: NCT02963779

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore

A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine

Phase 3

Completed

Conditions: Migraine

Interventions: Drug: Galcanezumab

First Posted Date: 2016-11-08

Last Posted Date: 2020-09-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 311

Registration Number: NCT02959190

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamaguchi, Japan
🇯🇵
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ōsaka, Japan

A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine

Phase 2

Completed

Conditions: Migraine

Interventions: Drug: Placebo
Drug: Galcanezumab

First Posted Date: 2016-11-08

Last Posted Date: 2021-04-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 459

Registration Number: NCT02959177

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamanashi, Japan
🇯🇵
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Nishinomiya, Japan
🇯🇵
"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Nishinomiya, Japan

A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY2963016

First Posted Date: 2016-11-04

Last Posted Date: 2017-03-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 127

Registration Number: NCT02955953

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore

A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)

Active, not recruiting

Conditions: Mild Cognitive Impairment
Alzheimer Disease

Interventions: Drug: Florbetapir F 18 PET Scan

First Posted Date: 2016-11-01

Last Posted Date: 2024-10-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1400

Registration Number: NCT02951598

Locations: 🇺🇸
Global Clinical Trials, Irvine, California, United States
🇺🇸
Irvine Clinical Research Center, Irvine, California, United States
🇺🇸
Colorado Neurological Institute, Englewood, Colorado, United States

and more 73 locations

A Study of LY3185643 and rGlucagon in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: rGlucagon
Drug: LY3185643

First Posted Date: 2016-11-01

Last Posted Date: 2019-09-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 23

Registration Number: NCT02951780

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore

A Study of LY900014 Formulation in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY900014
Drug: Insulin Lispro

First Posted Date: 2016-10-24

Last Posted Date: 2020-04-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 32

Registration Number: NCT02942654

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore

A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: LY3209590
Drug: Insulin Glargine

First Posted Date: 2016-10-24

Last Posted Date: 2017-11-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 80

Registration Number: NCT02942914

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Withdrawn

Conditions: Locally Advanced Squamous Non-Small Cell Lung Cancer
Metastatic Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Necitumumab
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2016-10-21

Last Posted Date: 2019-09-27

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT02941601

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
🇺🇸
Fairview Southdale Oncology Clinic, Edina, Minnesota, United States

A Study of LY3200882 in Participants With Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumor

Interventions: Drug: LY3200882
Drug: Cisplatin
Drug: LY3300054
Drug: Gemcitabine
Drug: nab-Paclitaxel
Radiation: Intensity Modulated Radiotherapy

First Posted Date: 2016-10-18

Last Posted Date: 2024-06-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 223

Registration Number: NCT02937272

Locations: 🇦🇺
St Vincent's Hospital Sydney, Sydney, New South Wales, Australia
🇦🇺
Greenslopes Private Hospital, Greenslopes, Queensland, Australia
🇫🇷
CHRU de Lille, Lille, France

and more 15 locations

Home Terms & Conditions Privacy Policy